Zevra Therapeutics Inc
ZVRA
Get informed when a big investor buys or sells
+ FollowMarket Cap$754.9M
Close$
$-10.42
183.2% downside
Current Fair Value
183.2% downsideOvervalued by 183.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $754.90 Million |
|---|---|
| Enterprise Value | $680.81 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.4 |
| Beta | 0.85 |
| Outstanding Shares | 58,405,955 |
Return
| Return on Equity | 59.94% |
|---|---|
| Return on Assets | 44.28% |
| Return on Invested Capital | -3.06% |
Valuation & Multiples
| P/E Ratio | 5.86 |
|---|---|
| PEG | -0.44 |
| Price to Sales | 6.26 |
| Price to Book Ratio | 4.17 |
| Enterprise Value to Revenue | 5.57 |
| Enterprise Value to EBIT | -96.08 |
| Enterprise Value to Net Income | 5 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$31.96 M
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$0.08
Average shareholder expectationRevenue Estimate
$33.85 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 192.44% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.56%▼ 69.18% |
|---|---|
| Total Invested | $13.06M▼ 96.60% |
| Investors Holding | 11▼ 147.00% |
ESG Score
No data
About Zevra Therapeutics Inc
24 employees
CEO: Travis Mickle KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its...